Opioids and their receptors have an important role in analgesia and alcohol and substance use disorders (ASUD). We have identified several naturally occurring amino acid changing variants of the human mu-opioid receptor (MOR), and assessed the functional consequences of these previously undescribed variants in stably expressing cell lines. Several of these variants had altered trafficking and signaling properties. We found that an L85I variant showed significant internalization in response to morphine, in contrast to the WT MOR, which did not internalize in response to morphine. Also, when L85I and WT receptor were coexpressed, WT MOR internalized with the L85I MOR, suggesting that, in the heterozygous condition, the L85I phenotype would be dominant. This finding is potentially important, because receptor internalization has been associated with development of tolerance to opiate analgesics. In contrast, an R181C variant abolished both signaling and internalization in response to saturating doses of the hydrolysis-resistant enkephalin [D-Ala2,N-MePhe4,Gly5-ol]enkephalin (DAMGO). Coexpression of the R181C and WT receptor led to independent trafficking of the 2 receptors. S42T and C192F variants showed a rightward shift in potency of both morphine and DAMGO, whereas the S147C variant displayed a subtle leftward shift in morphine potency. These data suggest that these and other such variants may have clinical relevance to opioid responsiveness to both endogenous ligands and exogenous drugs, and could influence a broad range of phenotypes, including ASUD, pain responses, and the development of tolerance to morphine.
Opioids and their receptors have an important role in analgesia and alcohol and substance use disorders (ASUD). We have identified several naturally occurring amino acid changing variants of the human mu-opioid receptor (MOR), and assessed the functional consequences of these previously undescribed variants in stably expressing cell lines. Several of these variants had altered trafficking and signaling properties. We found that an L85I variant showed significant internalization in response to morphine, in contrast to the WT MOR, which did not internalize in response to morphine. Also, when L85I and WT receptor were coexpressed, WT MOR internalized with the L85I MOR, suggesting that, in the heterozygous condition, the L85I phenotype would be dominant. This finding is potentially important, because receptor internalization has been associated with development of tolerance to opiate analgesics. In contrast, an R181C variant abolished both signaling and internalization in response to saturating doses of the hydrolysis-resistant enkephalin [D-Ala2,N-MePhe4,Gly5-ol]enkephalin (DAMGO). Coexpression of the R181C and WT receptor led to independent trafficking of the 2 receptors. S42T and C192F variants showed a rightward shift in potency of both morphine and DAMGO, whereas the S147C variant displayed a subtle leftward shift in morphine potency. These data suggest that these and other such variants may have clinical relevance to opioid responsiveness to both endogenous ligands and exogenous drugs, and could influence a broad range of phenotypes, including ASUD, pain responses, and the development of tolerance to morphine.
OPRM1 ͉ SNP ͉ tolerance ͉ morphine ͉ opiate P harmacological studies have demonstrated that morphine, other clinically useful opiates, and heroin act by activating the mu-opioid receptor (MOR) coded in the human by the OPRM1 gene. Because activation of MOR results in analgesia, morphine and its derivatives are widely used as analgesics. Also, the MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via modulation of the meso-limbic dopamine system (1, 2) . Genetargeting experiments have confirmed the absence of morphineinduced analgesia, reward, and physical dependence in MOR knockout mice (3) . Binding of endogenous and exogenous opioids activates the MOR, resulting in G␣i stimulation and a consequent decrease in cAMP levels. Activity of the receptor is regulated at many levels, including internalization (4, 5) , which removes activated receptors to an internal compartment. Internalized receptors can be recycled back to the membrane, where it can bind ligand and be reactivated. This trafficking is thought to contribute to both attenuated opioid signaling during acute agonist stimulation and the recovery of responsiveness on removal of the agonist (6) . Although most opiates promote MOR internalization via ␤-arrestin mediated pathways, activation of MORs by morphine results in very little internalization (5, 7, 8) . It has been suggested that this aberrant trafficking of MORs results in prolonged activation of the receptor, leading to compensatory changes that result in tolerance to therapeutic doses of morphine (9, 10) .
Because of the central role of MOR in analgesia and alcohol and substance use disorders (ASUD), numerous studies have addressed the potential contribution of alternative splicing, oligomerization, and naturally-occurring sequence variation in the OPRM1 gene to substance abuse susceptibility and variable analgesic response (11) (12) (13) (14) (15) . Also, splice variants of MOR have been reported for rodents and humans (16) , and can result in isoforms with varying trafficking and signaling properties (17) . Also, the MOR has been shown to oligomerize with other opioid receptors (18, 19) , and with receptors in other classes (20, 21) , which can significantly alter receptor function (10, 22) . Sequencing of OPRM1 has identified a number of nonsynonymous SNPs that alter the resulting protein. However, only the relatively frequent N40D variant has been extensively characterized to date (23) (24) (25) . Although rarer variants may not explain the genetic basis for ASUD or other clinical phenotypes, they can have an important role in elucidating the function of opioid receptors and circuits. The rare variants N152D, R265H, and S268P have been functionally characterized (26) , and the S268P variant was shown to be a loss-of-function mutation for the MOR. The current study characterizes the signaling and trafficking properties of 8, nonsynonymous variants discovered by sequencing of OPRM1 in a human population.
Results

Identification of Variants.
DNA sequencing of each of the coding regions of OPRM1 in the San Diego Sibling Pair study cohort of 550 subjects revealed significant variability in genetic sequence. Sixty-eight variants were identified in the coding region, flanking sequences, and conserved noncoding regions. Eight predicted a change in amino acid sequence, and are shown in Fig. 1 . Although the majority of the nonsynonymous polymorphisms identified were rare (allelic frequencies 0.001-0.004), some of the more common, previously reported SNPs (A6V, allelic frequency 0.013; N40D, allelic frequency 0.166) were also observed. Five of the variants discovered (S42T, L85I, R181C, C192F, and T205M) have not been previously described. With respect to location, 3 variants (A6V, N40D, and S42T) were shown to be present in extracellular domains of the receptor, 4 were in transmembrane regions (L85I, S147C, C192F, and T205M), and 1 was intracellular (R181C). Analysis of the functional consequence of the previously uncharacterized amino acid substitutions with Polyphen (http://genetics.bwh.harvard-.edu/pph/) predicted 4 of the variants (S42T, R181C, C192F, and T205M) to be deleterious to the normal functioning of the receptor. L85I was predicted to be benign.
Functional Analysis of Variants. HEK293 cells stably expressing FLAG-tagged, WT MOR1, or the variants L85I, R181C, or T205M were initially investigated for alterations in receptor trafficking. Live cells were incubated with anti-FLAG M1 antibody to selectively label surface receptors and then stimulated with either 10 M [D-Ala2,N-MePhe4,Gly5-ol]enkephalin (DAMGO) or morphine, fixed, permeabilized, and incubated with a fluorescent secondary antibody. As shown in Fig. 2 , the WT MOR1 remained primarily on the surface after activation with morphine or with no drug, whereas DAMGO induced substantial endocytosis (Fig. 2 A) . T205M showed a trafficking pattern similar to that of the WT MOR (Fig. 2B) . In contrast, the L85I variant was internalized in response to not only DAMGO, but also morphine (Fig. 2C) , whereas the R181C variant showed little to no internalization in response to DAMGO (Fig. 2D) . These results were replicated in multiple clones, confirming that the observed phenotype was not due to clonal variation (Fig. S1 ). To confirm these trafficking profiles, we performed biotin-protection assays. Cells stably expressing FLAG-tagged, WT MOR (Fig. 2E) , L85I (Fig. 2F ), or R181C (Fig. 2G) were labeled with a thio-cleavable biotin label and treated with agonist. After agonist stimulation with morphine, receptors remaining at the surface were ''stripped'' of biotin with membrane-impermeant reducing agent; internalized ''protected'' receptors were visualized with streptavidin overlay. As expected, the WT (MOR1) did show internalization in response to DAMGO, but not with morphine (Fig. 2E) . Surprisingly, the L85I variant showed endocytosis with both DAMGO and morphine (Fig. 2F ), confirming the immunohistochemical data shown above (Fig. 2C) . Biotin protection assays also confirmed the failure of R181C internalization in response to DAMGO stimulation (Fig. 2G) .
Activity Assays. We next examined whether altered trafficking of the variants was accompanied by changes in signaling, testing G protein signaling in our MOR cell lines with a calcium-based activity assay (27) . As seen in Table 1 , the EC 50 s of both DAMGO and morphine were similar and in the nM range for MOR1, L85I, and T205M (2-way ANOVA). Thus, the internalization of the L85I variant receptor by morphine cannot be attributed to enhanced potency at the L85I receptor. Also, statistical analysis indicated that the maximal effect (E max ) values for MOR1, T205M, and L85I did not differ significantly from each other. R181C showed no agonist response to either DAMGO or morphine in either of the independent stable clones tested, suggesting that lack of internalization could reflect the inability of the receptor to signal through G protein, although G protein coupling is not an absolute requirement for MOR internalization (28) , and there is even evidence of some antagonists promoting G protein-couplied receptor (GPCR) internalization (29) . The dose-response curves are shown in Fig. S2 .
Binding Assays. Failure to bind agonist could explain the absence of signaling observed in R181C. To examine this possibility, we assessed DAMGO binding in the R181C and other variants. DAMGO bound to all variants, including R181C, in the nM affinity range (Table 2) , and no significant differences in K d were observed (1-way ANOVA). Differences in B max were observed, with clones for T205M showing lower levels of expression (P Ͻ Functional Consequence of Having a Single Mutant Allele. With rare mutations, minor allele homozygotes will likely not be seen outside of highly inbred populations. Indeed, both L85I and R181C have been found only in the heterozygous condition in our population. In several instances, mutant GPCRs with altered trafficking properties have been shown to affect the trafficking of the WT receptor, presumably due to receptor oligomerization (10) , such as the CCR5 mutant that protects against HIV (30) . Thus, although it is possible that only half of the MORs in each heterozygous individual expressing a rare variant would drive aberrant trafficking or signaling (assuming identical transcription and translation), it is also possible that either the WT or the variant could show dominance, resulting in either no trafficking of either or trafficking of both. To examine whether trafficking of WT receptors was altered in the presence of an allelic variant or vice versa, we simulated a heterozygote by generating HEK293 cells stably expressing both a FLAG-tagged mutant receptor and an HA-tagged WT receptor. In cells expressing both WT and R181C receptors, WT, but not the R181C variant, internalizes in response to DAMGO (Fig. 3A) . Biotin protection assays confirmed these findings (Fig. 3B) . Also, the biotin protection assay demonstrates that internalization of the WT MOR in response to 10 M DAMGO is not adversely affected by the presence of the noninternalizing R181C variant. These data suggest either that WT MOR and R181C do not form dimers with each other, or that any such dimerization is labile and the receptors separate at the surface and traffic independently. In contrast, cells expressing the L85I variant together with the WT MOR internalize both receptors in response to morphine as shown by both immunofluorescence (Fig. 4A ) and biotin protection assay (Fig. 4B) . Thus, L85I appears to be a dominant mutation with respect to the trafficking phenotype.
The cAMP Superactivation and Tolerance in the L85I Variant. Cells in culture expressing MORs show compensatory changes in signal transduction, including up-regulation of cAMP, after chronic treatment with morphine (31). These changes, including cAMP superactivation, are thought to underlie, at least in part, tolerance and dependence to morphine (32) . It has been shown previously that MOR mutants engineered to undergo morphineinduced internalization demonstrate reduced propensity to cause these adaptive responses in heterologous cells (9) . Also, mice expressing these mutant receptors show reduced morphine tolerance and dependence (33) . Here, we have identified a naturally occurring variant that undergoes internalization with morphine without showing changes in morphine potency. We predicted that cells expressing the L85I MOR variant would, therefore, show reduced tolerance and dependence as assessed by cAMP responses. To examine this possibility, we ascertained acute drug responses before and after chronic morphine treatment, as well as cAMP superactivation in cells expressing MOR or L85I. Chronic morphine treatment of cells expressing WT Stably expressing MOR variant clones were transiently transfected with a mutant Gi construct such that activation of the receptor would result in an efflux of intracellular calcium that could be measured with a fluorescent dye. Each data point is an average of at least 3 independent experiments in triplicate. NA, not applicable. MOR1 led to increased cAMP levels or ''superactivation'' (see diamonds in Fig. 5A ). Significant superactivation was observed after pretreatment with 10 and 100 nM morphine. In contrast, DAMGO at these doses did not promote superactivation, consistent with the hypothesis that internalization prevents this effect (see triangles in Fig. 5A ). Importantly, superactivation was significantly reduced (P Ͻ 0.001; 2-way ANOVA, Bonferroni post hoc test) in response to morphine at the 10 and 100 nM doses in cells expressing the L85I variant (see squares in Fig. 5A ). To assess whether tolerance to morphine was likewise reduced in cells expressing L85I, we used a morphine rechallenge experiment. Cells were treated chronically with morphine (100 nM, 14 h) or left untreated. After a withdrawal phase initiated by 3 washes, a 4-hr acute phase was initiated, with or without morphine (10 nM), and CRE-luciferase expression measured. CRE-luciferase expression in untreated, morphine-naive cells was defined as 1. As seen in Fig. 5B , acute administration of morphine to cells containing WT results in a decrease in CRE-luciferase expression due to Gi-mediated signaling (bar 2). Chronic administration of morphine leads to high levels of CRE luciferase expression reflecting cAMP superactivation (bar 3). As a consequence of this superactivation, the level of CREluciferase expression was significantly higher in the chronically treated WT MOR cells receiving a morphine rechallenge than in the naive WT MOR cells that received a single dose of acute morphine (bar 2 vs. bar 4, P Ͻ 0.001; 1-way ANOVA, Tukey post hoc test). This demonstrates that the cells had become tolerant to the effects of morphine. Also, tolerance was reduced in analogously treated L85I-containing cells (compare bars 4 and 8; P Ͻ 0.001; 1-way ANOVA, Tukey post hoc test), due to lower superactivation seen in L85I containing cells (bar 3 vs. bar 6).
The other 4 variants we identified (A6V, S42T, S147C, and C192F) showed no changes in morphine or DAMGO-induced internalization by immunofluorescence (Fig. S4) , although each of these variants was examined only in the context of the MOR1A splice variant backbone that lacks 12 aa coded by exon 4 (34, 35) . To determine whether the MOR1A background altered the activity of the MOR protein, we compared FLAGtagged MOR1 receptors to MOR1A receptors. We also included 4 additional variants on the MOR1A backbone. DAMGO and morphine had potency in the nanomolar range on MOR1, MOR1A, A6V-MOR1A, and S147C-MOR1A, but only Ͼ150 nM potency on S42C-MOR1A and C192F-MOR1A, indicated by a rightward shift in the dose-response curves for both DAMGO and morphine in the S42T and C192F variants (Table  3 ; Fig. S5A ). Also, morphine was more potent on the S147CMOR1A variant than on the WT receptor (P Ͻ 0.01; 2-way ANOVA, Bonferroni post hoc test). No significant differences in efficacies (E max ) of DAMGO or morphine were observed when MOR1A, A6V-MOR1A, S42T-MOR1A, and S147C-MOR1a were compared with MOR1. However, E max of both morphine and DAMGO were significantly different between S147C and MOR1A (P Ͻ 0.01 and P Ͻ 0.05, respectively; 2-way ANOVA, Bonferroni post hoc test). E max of DAMGO also differed significantly between the A6V variant and MOR1A (P Ͻ 0.05). There were no significant differences in binding affinity for DAMGO in these variants (Table 4 ; Fig. S5B ).
Discussion
Individuals vary in their sensitivity to therapeutically administered opiates. Some of this variability may be due to variations in amino acid sequence in the MOR gene (36) . Given the importance of the MOR in clinical pain treatment, as well as ASUD, a concerted effort to resequence the OPRM1 gene has been put forth (37) . Extending such studies, we have resequenced the coding regions of the human OPRM1 gene and identified 68 variants, 8 of which alter the protein sequence of the receptor. Thus, the MOR appears to be quite polymorphic, with almost one-third of the subjects sequenced carrying at least 1 nonsynonymous SNP in the OPRM1 sequence.
The R181C variant is a signaling dead variant that does not internalize in response to 10 M DAMGO. However, this variant receptor does show a similar agonist binding profile to WT, indicating that the amino acid substitution does not alter ligand binding. This result is perhaps not surprising given the intracellular location of the variation. However, once bound, the agonist does not result in G protein mediated signaling and subsequent events in the cascade that culminate in internalization. Also, the proband carrying this variant is a heterozygote and, thus, likely has only half the functional receptors present in a normal individual. Previous experiments have demonstrated a 60% decrease in MOR binding (38) , as well as reduced sensitivity to morphine in heterozygous MOR deficient mice (39, 40) . Thus, an individual carrying this variant may demonstrate an altered response to therapeutically administered opiates or endogenous beta endorphin.
Although morphine treatment of HEK cells cotransfected with WT MOR1 and a recycling chimeric MOR1 (D-MOR) results in internalization of the WT MOR protein (10), coexpression of MOR1 did not lead to DAMGO-mediated internalization of the R181C variant in our cell system. Also, R181C did not prevent the WT MOR1 from DAMGO-mediated internalization. Together, these data suggest that R181C does not form stable oligomers with WT MOR1, possibly due to the variant cysteine residue forming inappropriate disulfide bonds and altering the topology and/or function of R181C.
Morphine-stimulated MORs have been shown, with few exceptions (41, 42) , to elude internalization (43) . It has been suggested that this aberrant trafficking of MORs results in prolonged activation of the MORs, leading to compensatory changes that result in tolerance to morphine. The L85I variant is interesting in that, although this variant receptor internalized normally in response to DAMGO in a HEK cell system, internalization was also seen in response to morphine. This finding was surprising, given that the replacement of a leucine by an isoleucine was not predicted to have a major consequence for the structure or function of the variant protein. However, there are other reports of seemingly benign amino acid substitutions dramatically altering protein function of GPCRs. Substitution of a leucine for an isoleucine at position 542 in the lutenizing hormone receptor, for example, leads to elevated cAMP production (44) . Coexpression of WT with the L85I variant does not mitigate the internalization to morphine. Also, both cAMP up-regulation and tolerance to morphine are reduced in cells expressing the L85I variant. These in vitro findings can now be extended to animal systems by creating L85I knock-in mice. Also, we are in the unique position of being able to ascertain morphine tolerance in human carriers of the L85I allele, thus, exploring the relationship between receptor endocytosis and tolerance to opiates in humans.
Functional differences have been reported between Cterminal splice variants of the OPRM1 gene in mice (45) and rats (17) . When we compared MOR1 receptors to MOR1A receptors lacking the 12 aa coded by exon 4, we found that the 2 receptors had similar binding, activation, and trafficking profiles. However, we cannot exclude the possibility that closer examination of MOR1 and MOR1A could reveal important functional differences between the 2 isoforms. Interestingly, the S42T-MOR1A and C192F MOR1A variants demonstrated reduced potency for both DAMGO and morphine, whereas morphine had increased potency at the S147C-MOR1A receptor. Thus, 5 of the 8 nonsynonymous variants tested appear to have consequences on receptor function.
In conclusion, we and others have identified a number of polymorphisms in OPRM1 that may explain the variability seen in the clinical response to opiates, both from an analgesic and ASUD stand-point. Further functional and clinical characterization of these variants should help provide valuable insight into the functioning of the MOR.
Materials and Methods
Identification of Variants. The subjects used were from the San Diego Sibling Pair study (46, 47) , and consisted of college age students from the San Diego (mean ؎ SEM) for morphine and DAMGO in MOR1, MOR1A,  A6V-MOR1A, S42T-MOR1A, S147C-MOR1A, or C192F-MOR1A metropolitan area. This collection was designed to identify families enriched for alcoholism susceptibility genes. Genomic DNA was extracted from anticoagulated venous blood samples using the PureGene DNA extraction kit (Gentra) according to manufacturer protocols. PCR primers for the coding regions of the MOR were generated using Exon Primer (http://ihg.gsf.de/ihg/ ExonPrimer.html) and synthesized commercially. PCRs were performed in 10-L volumes using Ampli-Taq Gold (ABI), and the PCR products then sequenced on an ABI 3730XL sequencer using standard protocols. The sequence data obtained was imported into Mutation Surveyor and polymorphisms identified. Each polymorphism was manually checked for confirmation.
Generation of Variants. WT MOR1 or MOR1A was cloned into pCDNA3.1 Zeo or Hygro (Invitrogen), downstream of an in-frame signal sequence and FLAG epitope as described previously (48) . Quickchange (Stratagene) was used to generate FLAG-tagged constructs of the point mutations identified. The constructs were transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen) and individual clones selected using appropriate antibiotics. Double-stable cell lines were generated by cotransfecting cDNAs for FLAG-tagged mutant receptors concomitantly with HA-tagged MOR1 into HEK293 cells and selecting for clones with 2 antibiotics. Table 4 . Data represents at least 2 independent experiments in quintuplicate.
Characterization of
